Today: 9 July 2026
Big Funds Boost GM Holdings, But Filings Show the Details
29 May 2026
2 mins read

Big Funds Boost GM Holdings, But Filings Show the Details

Detroit, May 29, 2026, 07:02 EDT

GM picked up interest from big investors on Friday after MarketBeat said National Pension Service and Geode Capital Management bought GM stock in the fourth quarter. This comes after an earlier report this week that Allstate upped its stake too. The data is for last quarter, not current buying.

GM raised its 2026 core profit outlook last quarter and kept North America margins over 10%. That comes as investors look at tariffs, higher costs, and a slower electric vehicle rollout. Timing matters now.

Form 13F is the quarterly filing from big investment managers listing their holdings as of the end of the quarter. The data has a lag, and the SEC warns it’s pulled from what filers submit, not a replacement for reading the full reports.

National Pension Service boosted its stake in GM by 78.8% in Q4, MarketBeat reported. The fund bought 1,720,384 GM shares, closing December with 3,903,579 shares valued at $317.4 million. An SEC table for the quarter listed the same position for National Pension Service.

Geode bumped up its GM stake, raising it by 1.2% and picking up 267,477 more shares, MarketBeat said. That brought Geode’s total GM holding to 22,242,381 shares, valued at about $1.80 billion. The firm’s SEC filing showed two line items for GM that matched both the share count and value.

Allstate boosted its GM stake with a bigger percentage gain. The insurer more than doubled its GM holding, adding 37,229 shares for a total of 73,140 shares, according to MarketBeat. Its filing showed those 73,140 shares worth $5,947,745.

GM’s filings are drawing attention because of the company’s operating conditions. GM last month posted first-quarter revenue of $43.6 billion, net income to stockholders at $2.6 billion, and adjusted EBIT of $4.3 billion. The automaker lifted its 2026 EBIT-adjusted target by $500 million, setting a new range of $13.5 billion to $15.5 billion.

GM set a quarterly dividend of 18 cents per share, with payment going out June 18 to shareholders on record as of June 5. MarketBeat reported GM has a $6 billion share buyback plan in place, bringing more focus to returns for investors.

Mary Barra, GM’s chair and CEO, told shareholders the company has “solid momentum” in its core business and is operating in a “very dynamic environment.” GM said it led U.S. and Canadian sales, took 42% of the U.S. full-size pickup market, and was No. 2 in electric vehicles. Investors often track these numbers against Ford, Stellantis and Tesla. General Motors

GM’s results drew mixed reactions. GM CFO Paul Jacobson told Reuters the company hasn’t seen “any material changes to demand or mix thus far.” But JPMorgan analyst Ryan Brinkman said GM should get credit for lifting its forecast, given the “significant uncertainty and volatility” right now. Reuters

But GM’s downside risks are still clear. The automaker is sticking with its view that tariffs will knock $2.5 billion to $3.5 billion off profit this year, Reuters said. On top of that, it faces $1.5 billion to $2 billion in expected hits from higher costs for raw materials, chips and logistics. GM also took a $1.1 billion charge in the first quarter related to slower electric-vehicle programs.

The filings are more of an old snapshot than a new bullish sign, showing who held positions as GM moved into 2026 with higher guidance, more cash returns, and some cost pressure still in play. The real question is if those investors hang on when newer quarterly filings reflect what’s happened with the stock.

Roman Perkowski is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Cracow University of Economics, he previously worked in investment research and corporate finance. His coverage helps readers understand the key forces driving global financial markets and emerging industries.

Stock Market Today

  • Virax Biolabs Signs Exclusive Supply Pact With Fosun Diagnostics for Southeast Asia
    July 9, 2026, 8:49 AM EDT. Virax Biolabs Group Limited (NASDAQ: VRAX) has landed an exclusive commercial supply deal with Fosun Diagnostics to cover six Southeast Asian countries: Thailand, Vietnam, Indonesia, the Philippines, Singapore, and Malaysia. The agreement is for Virax's ImmuneSelect immune profiling products, separate from its diagnostic platform that's still in the works. Virax can now supply products right away through purchase orders, eyeing near-term revenue and a wider regional presence. Fosun Diagnostics, under Fosun Pharma, will use its network for distribution across the region. The agreement leaves room for more products, higher volume, and the chance of OEM or private-label deals down the line. Pricing is set up for scale. The deal moves Virax further into the ASEAN diagnostics market.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

US Stock Market Today: Live Updates 28.05.2026

IREN Shares Slide, Bringing Dell AI Deal and $4.4 Billion Test Into Focus
Next Story

IREN Shares Slide, Bringing Dell AI Deal and $4.4 Billion Test Into Focus

Go toTop